The domestic vaccine market is worth KRW 700 billion (as of 2014). With the expansion of national mandatory vaccination and a paradigm shift in medical service, it is expected to experience an annual growth of 8% or more. Most premium vaccines distributed in Korea, however, are produced by multinational pharmaceutical companies. Under these circumstances, the government has announced a plan to increase the rate of self-supply of vaccines and expand its support to enhance the production capacity of domestic pharmaceutical companies.
SK Bioscience’s Life Science Research Institute has built a wide-ranging product portfolio and made continuous investments in the vaccine sector, which will serve as pivotal growth engines in the future Life Science business. We are continuously striving to achieve a competitive edge in the R&D sector to reach the goal of “promoting human health.”
In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccine (PCV). It also succeeded in developing numerous premium vaccine products, including Korea’s first cell culture-derived trivalent influenza vaccine (2014) and the world’s first cell culture-derived quadrivalent influenza vaccine (2015).
It has acquired marketing approval for “SKYZOSTER”, a shingles vaccine (2017), and SKY Varicella, a varicella vaccine (2018). The company will also apply for WHO prequalification review to pioneer the global market for SKYCellflu and aims to receive approval by 2018. SK Bioscience will endeavor to enhance the domestic medical industry and establish a dominant position in the field of vaccines through our globally recognized vaccine production facilities and R&D capability.See more